

CHINA CONSUMER STAPLES

May Check-in: Sequential softness on unfavorable weather/consumption sentiment; beer under pressure/dairy more resilient; Value retailers accelerating store openings

We noted a further deceleration/softness in May with continued unfavorable weather and likely weaker consumption sentiment. In particular, **beer** continued to face volume pressure under rainy weather (especially in South China) and still bumpy recovery in on-trade consumption, seeing volume declines widened sequentially vs. April. **Condiments** outperformed with stronger resilience and **dairy** continued demand recovery for liquid milk, with leading companies sustaining positive sales growth despite some deceleration, where we highlight Haitian's continued solid trends. **Value retailers** accelerated store openings with Busy Ming and Wanchen each adding 1k net adds in May vs. 400-600 in Feb-Apr. **Into June, we highlight: 1)** A low base gradually starts to kick in for on-trade channels/Spirits (2025 May/June/July catering retail sales at 5.9%/0.9%/1.1% yoy); **2)** More cost headwinds kicking in despite slightly MoM moderation in PET prices, while most staples companies remain cautious on pricing actions (CR Beer's price hike on Heineken canned beer since late May remains regional); **3)** Per-store GMV trends for value retailers remain a key focus as store openings further accelerate.

May trends by subsector based on channel checks: **Beer** volumes were sequentially weaker in May vs. April due to continued unfavorable weather conditions. In particular, the heavier rainfall seen across South/Central China in April appears to have extended into North China in May, according to the China Meteorological Administration. **Tsingtao's** volume decline widened to -9% in May, while **Budweiser's** volume decline remained in the low-teens% and **Chongqing Brewery's** volume continued to contract; **CR Beer** also saw a slight sequential slowdown vs. April but meaningfully outperforming peers. Meanwhile, **condiments/frozen food** remained relatively resilient among leading players: **Haitian's** sales growth largely maintained at HSD~DD% in May vs. HSD% in April, **Yihai's** third-party sales sustained DD% growth in Jan-May, but **Anjoy's** growth moderated sequentially to HSD% in May despite easier comp. **Beverages sell-through** also softened in Apr/May relative to 1Q on unfavorable weather (meanwhile, beverage-related social retail sales still grew 3.6% yoy in April, continuing to outperform overall consumer goods retail sales excluding autos at +1.8% yoy). **Nongfu's** bottled water slowed down in May (with water industry likely seeing decline), while sugar-free tea sustained strong momentum at +25% yoy growth, though slightly moderated vs. Apr. **Eastroc** saw energy drinks slightly accelerating to mid teens % growth while Bushuila shipment also accelerated to

Leaf Liu
+852-3966-4169 | leaf.liu@gs.com
Goldman Sachs (Asia) L.L.C.

Valerie Zhou
+852-2978-0820 | valerie.zhou@gs.com
Goldman Sachs (Asia) L.L.C.

Christina Liu
+852-2978-6983 | christina.liu@gs.com
Goldman Sachs (Asia) L.L.C.

Goldman Sachs does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For Reg AC certification and other important disclosures, see the Disclosure Appendix, or go to www.gs.com/research/hedge.html. Analysts employed by non-US affiliates are not registered/qualified as research analysts with FINRA in the U.S.

20~30% in April-May post destocking vs. 1Q26. **Value retailers'** store opening pace further accelerated in May with c.900/c.1,000+ net adds for **Busy Ming/Wanchen** per our channel checks, while Wanchen's positive avg. per-store daily GMV sustained positive growth (including new stores). **Snacks brands** especially Yankershop/Weilong will likely continue to benefit from value retailers' strong store expansion with high-30s%/mid-30% sales exposure respectively in the value retailers channel. Meanwhile, Yankershop is seeing narrowing decline in traditional unpacked channels in 2QTD while Weilong is muted. We expect Yankershop/Weilong to remain on track to deliver konjac growth of 30%+/c.20% yoy in 2Q/1H26.

Key stock ideas: We continue to highlight **dairy (Mengniu)** on S/D cycle re-balancing, **F&B value retailers (Busy Ming/Wanchen)** with strong expansion trend in white space and leading players' reaffirmed stances towards a healthy competition environment, **Nongfu** as best positioned to navigate rising cost inflation challenges with strong portfolio/new product launches, and **pork (WH Group)** on cost tailwinds/efficiency gains. We continue to like **Haitian-H/Yihai** supported by solid execution for market share gain and dividend (Exhibit 15). We also reiterate our constructive view on **Moutai/CR Beer/Yankershop**.

The authors would like to thank Lily Qi for her contribution to this report.

Related Read:

China Staples: Value Retailers: Busy Ming/Wanchen officially reiterated commitment to healthy competitive environment; Store open acceleration in May; Buy

China Snacks: 2Q/1H early color: Konjac resilience for growth and cost benefits, though other products see short-term softness; Buy Yankershop and Weilong

China Beverages: Factoring in higher and more enduring cost inflation; Competition yet to rationalize; Who is best positioned?

China Dairy: Navigating the S/D inflection and IMF divergence; Buy Mengniu/Yili on attractive risk reward

China Consumer Staples Cost Index Tracker: May 2026: PET cost easing but still high; Aluminum sequentially trended down

May Check-in: Sequential volume moderation except for resilient condiment/dairy

Beer Monthly Tracker

Exhibit 1: Monthly volume table 2024-2026 by GSe

	Jan	Feb	March	April	May	Jun	2026E Jul	Aug	Sep	Oct	Nov	Dec	2026E Jan	Feb	Mar	Apr	May
CRB		up MSD%	positive growth	positive growth, slightly faster than 1Q	up LSD%	minor positive growth	up 4-5%	up LSD%	up LSD%	slightly positive	flatfish to slightly positive	flatfish	positive	Positive growth ; Jan+Feb Heineken up by DD%	Slightly growth	Up LSD%, similar to 1Q26	slower than April trend
Bud APAC China		down MSD%	decline	down LSD%	down HSD%	down HSD%	down low teens%	down c.Mid teens%	down SD%	Minor decline	Down 7-8%	down DD%	Likely negative	Volume under pressure	up 3-4%	Volume declined by low teens% (super premium up by low teens%, premium down by low teens%, core down by mid teens%)	down 12-13%
Tsingtao	down MSD%	up MSD%	up DD%	down LSD%	up MSD%	flatfish	flatfish	up 1.5%	up 3%	down HSD%	up 1.1%	up 12%	volume down c.MSD%	down 9.5%	up 5-6%	Volume declined by 7.5%	down 9%
Chongqing		positive growth	up LSD%	largely steady	flatfish to minor decline	down LSD%	minor decline	down LSD%	up MSD%	Minor decline	up slightly %	up slightly %	Jan-Feb negative on relatively high base		positive growth	Volume down by LSD%	decline
Bairun		RTD cocktails down c.10%			RTD cocktail sales down teens%		RTD cocktail down c.high teens%	DD% growth in RTD drinks due to low base	flatfish		offline shipment up 30%		up DD%+ on calendar shift				
Yanjing																SD% positive growth	
Industry	-4.90%	1.90%	4.80%	1.30%	-0.20%	1.90%	-1.80%	3.10%	-1.00%	-5.80%	-8.70%	6.50%	0.20%	-0.10%			

Source: Goldman Sachs Global Investment Research

F&B value retailer monthly store opening tracker and per Store GMV tracker

Exhibit 2: Value retailer monthly store opening table

Store number monthly tracker	Jan-25	Feb-25	Mar-25	Apr-25	May-25	Jun-25	Jul-25	Aug-25	Sep-25	Oct-25	Nov-25	Dec-25	Jan-26	Feb-26	Mar-26	Apr-26	May-26
Busy Ming	14,737	14,956	15,152	15,474	15,989	16,783	17,584	18,551	19,517	20,513	21,041	21,948	22,801	23,291	23,771	24,271	25178
Net add	343	219	196	322	515	794	801	967	967	996	528	907	853	490	480	500	907
store open %	2.4%	1.5%	1.3%	2.1%	3.3%	5.0%	4.8%	5.5%	5.2%	5.1%	2.6%	4.3%	3.9%	2.1%	2.1%	2.1%	3.7%
Haoxianglai only	12,977	13,325	13,632	14,119	14,356	15,365	15,565	15,612	16,320	16,619	16,626	17,248	17,834	18,434	18,909	19,509	20,560
Net add	1,229	348	307	487	237	1,009	200	47	708	299	7	622	586	600	475	600	1,051
store open %	10.5%	2.7%	2.3%	3.6%	1.7%	7.0%	1.3%	0.3%	4.5%	1.8%	0.0%	3.7%	3.4%	3.4%	2.6%	3.2%	5.4%

The data may have time/lagging differences vs the act. numbers

Source: Douyin, Wechat official accounts, GeoQ, Company data, Goldman Sachs Global Investment Research

Exhibit 3: Avg GMV per store summary (GSe)

Store performance: avg GMV per store yoy	1Q25	2Q25	3Q25	4Q25	Jan-Feb 2026	Apr-26	May-26
Busy Ming	-MSD% yoy		Down SD% yoy	Flatfish yoy	HSD% growth yoy		
Wanchen	Down mid teens%	Down mid teens%	Down SD%	MSD% decline yoy	9% yoy	Up SD%	positive average daily GMV

Source: Company data, Goldman Sachs Global Investment Research

Beverage Monthly Tracker

Exhibit 4: Beverage monthly data summary

		Jan-25	Feb-25	Mar-25	Apr-25	May-25	Jun-25	Jul-25	Aug-25	Sep-25	Oct-25	Nov-25	Dec-25	Jan-26	Feb-26	Mar-26	Apr-26	May-26
Nongfu	Water yoy %	down DD%	positive growth	up DD%	up DD%	up 10%	up 15%	up DD%	up strong DD% on base	decline on high base	up c.20% (regional difference)	up DD%	up high teens%	up 20%	up 15-20%	positive growth	Growth deceleration for water	Slow down
	Beverage yoy % (Oriental Leaf)		up DD%	positive growth	Oriental Leaf up 8%	Oriental Leaf up 25%	Sugar free tea up strong DD%	Sugar free tea up strong DD% on base	Sugar free tea up strong DD% on base	Tea maintained strong momentum							up DD% for OL tea	Non-sugar tea up 25% (sequentially slow down on base comp)
	Water: green water portion %																	
	Water AC Nielsen market share %																	
	Overall yoy %	down DD%	up teens%	up DD%	up 20%+	up 25%	up DD%	up DD%	up DD%	up DD%	up c.20%	up DD%, Fiscal year quota completed	up c.20%	up DD%				
CR Bev	Water yoy %	up 12%		Steady yoy			up LSD%		Volume positive, but still under heavy discount					positive growth				
	Volume yoy%							Volume down SD%										
	Beverage yoy %	up 8%		up 30%-40%			up DD%											
	Volume yoy%							Volume up 20% (better than 2025)						positive growth				
Tingyi	Beverage sales yoy %	minor positive growth	SD% decline	PepsiCo: positive growth, others HSD% decline	PepsiCo: positive growth, others HSD% decline	PepsiCo: positive growth, others HSD% decline	PepsiCo: positive growth, others HSD% decline	PepsiCo: LSD+MSD%, positive growth, Others: MSD+HSD%, decline	PepsiCo: LSD+MSD%, positive growth, Others: MSD+HSD%, decline	Down MSD%	Non-carbonates down MSD+HSD%, Carbonates up LSD%, Overall down LSD%	SD% decline	Non-carbonates down HSD+DD%, Carbonates slight positive	Positive	up slightly from Tingyi beverage (non-carbonates)		Beverage up LSD%, Carbonates drink turn positive a 23%	
	Noodles sales yoy %	minor positive growth	SD% decline	Slight decline	LSD% decline	down MSD%	Up LSD%	SD% positive (raised price to mid-range noodles in Aug)	Up SD%	up LSD%	slight positive	Positive	up SD%			Positive, better than beverages		
UPC	Beverage sales yoy %	up SD%	up DD%	positive growth	up nearly 10%	up HSD%	up MSD%	Decline	Decline	Decline	Down MSD%	Down DD%	Decline	up HSD% to DD% on LMY shift	Jan-Feb up MSD%	positive growth	Overall Flatish	
	Noodles sales yoy %	up DD%	up HSD%	positive growth	up HSD%	up HSD%	Positive	Positive growth	Up LSD%	Positive growth	Retail sales up 58%-60% shipment grew at 25%+	Retail sales up 50% shipment grew at 35%+	Retail sales up 60% shipment grew at 35%+	Retail sales up c.60% shipment grew at DD%	Bushida sell-out in line with company expectation in Jan-Feb	Energy drink sell-out at DD% in line with company expectation. Bushida shipment also accelerated to 20-30% company expectation in March		
Eastoe	Overall yoy %	15% yoy	1.50% yoy	30%+ yoy	35% yoy	35% yoy	Energy drink 30% yoy	Retail momentum up c.50%	Retail momentum up c.50%+	Retail momentum up c.50%+								

Source: Goldman Sachs Global Investment Research

Dairy Monthly Tracker


Exhibit 5: Dairy monthly data summary

		Dec-24	Jan-25	Feb-25	Mar-25	Apr-25	May-25	Jun-25	Jul-25	Aug-25	Sep-25	Nov-25	Dec-25	Jan-26	Feb-26	Mar-26	Apr-26	May-26
Mengniu	Liquid milk sales yoy	Down LSD%	Down DD% (UHT milk down DD%, chilled yogurt flat, fresh milk up 30%)		Down	Flat (fresh milk up DD%, Deluxe down LSD%)	Mild decline to mild positive	Decline	Down low teens%	Down High teens%	Flatish to up LSD%	Down MSD%	10% decline	Positive growth HSD-DD% due to calendar shift	Up SD-HSD%	SD% positive growth	Liquid milk up LSD-MSD%	positive growth
Yili	Liquid milk sales yoy	Down 13%	Down 3% (Santini better than Basic UHT milk), Positive growth since Mar			Up SD% (Basic UHT milk better than Santini; positive for liquid milk in May)		Decline	Down LSD%	Down SD%	Steady to down SD%, 3Q liquid milk volume down c.8%	Down MSD%	SD% decline	Up MSD%	Up SD%	Steady yoy	Liquid milk up LSD %	

Source: Goldman Sachs Global Investment Research

Dairy supply-demand update


Exhibit 6: Raw milk price has stabilized at around Rmb3.0/kg since mid-June; 2Q26QTD avg. raw milk price yoy decline at LSD%



Latest price on May 14, 2026.

Source: Ministry of Agriculture and Rural Affairs

Exhibit 7: Cow herd size declined by 3.6% yoy in Apr 2026



Source: Ministry of Agriculture and Rural Affairs


Exhibit 8: Cow milk production was up 3.4% yoy in 1Q26

Exhibit 9: Production of dairy products in China increased by 1.5% yoy in Mar


Snacks Monthly Tracker

Condiments/Preparedood Monthly Tracker

Mashanging price tracker


Exhibit 12: Mengniu Deluxe saw stable price in East China while Yili decreased slightly; Yili Satine decreased slightly in South China in May

Source: Brand CT

Exhibit 13: Instant noodles prices mixed across brands while beverage/packaged water wholesale prices increased slightly in May

Due to data availability, wholesale price of Tingyi's products is based on the East China region, that of bottled water/ UPC noodles is based on South China, and that of Oriental Leaf is based on Central China; Nov data is applied to the Braised Beef Noodle Soup.

Source: Brand CT

Exhibit 14: Monthly production volumes point to a sequential deceleration in Apr

Source: NBS

Dividend Yield Summary

Exhibit 15: Yield summary table - staples companies with dividend yield > 4%

Company name	Ex dividend date	Dividend payout ratio		Dividend yield		FCF yield		FCF as % of sales		Net cash to equity		NP YoY 2027E
		2026	2027	2026	2027	2026	2027	2026	2027	2026	2027	
High dividend yield (>4%)												
Yihai International	5/28/2026	92%	92%	7.5%	8.3%	9.7%	10.5%	16%	16%	46%	49%	9%
Feihe	6/9/2026	99%	97%	7.5%	8.2%	7.8%	6.5%	11%	9%	28%	27%	10%
WH Group	5/13/2026	64%	64%	6.8%	6.8%	15.4%	13.2%	8%	7%	0%	4%	1%
Jiangsu Yanghe	5/20/2026	170%	150%	9.8%	9.7%	0.7%	4.6%	2%	14%	23%	15%	10%
Tingyi	6/10/2026	102%	101%	6.8%	7.1%	7.7%	9.5%	6%	7%	-22%	-13%	3%
UPC	6/9/2026	100%	100%	6.7%	7.0%	6.1%	6.6%	6%	6%	18%	18%	2%
Wuliangye Yibin	pending	117%	102%	6.3%	6.3%	-0.7%	7.5%	-4%	40%	87%	90%	12%
Shuanghui	4/29/2026	98%	98%	6.1%	5.9%	6.4%	6.5%	9%	9%	-7%	-5%	-6%
Qianhe Condiment	pending	100%	100%	6.0%	7.0%	3.9%	4.4%	10%	11%	32%	28%	14%
Tsingtao-H	6/30/2026	70%	73%	5.9%	6.7%	5.9%	7.4%	11%	13%	39%	39%	8%
Weilong Delicious	6/15/2026	60%	60%	5.5%	6.4%	8.1%	9.6%	17%	18%	77%	77%	15%
CR Beer	5/22/2026	62%	67%	5.4%	6.3%	11.7%	12.6%	21%	21%	23%	33%	7%
Budweiser APAC	5/20/2026	86%	87%	5.2%	5.8%	6.2%	7.3%	12%	14%	25%	27%	12%
Yili Industrial	6/5/2026	75%	75%	5.1%	5.6%	9.8%	10.8%	14%	15%	-29%	-13%	9%
Chongqing Brewery	pending	100%	100%	4.9%	5.4%	11.3%	12.6%	20%	21%	59%	80%	9%
Sichuan Teway	5/11/2026	100%	100%	4.6%	5.2%	2.6%	5.3%	10%	19%	34%	36%	11%
Fen Wine	pending	65%	65%	4.6%	5.0%	0.8%	6.6%	3%	26%	7%	12%	6%
Mengniu Dairy	6/9/2026	50%	52%	4.3%	5.2%	11.1%	11.6%	7%	7%	-5%	6%	9%
Tsingtao-A	6/30/2026	70%	73%	4.2%	4.8%	4.2%	5.2%	11%	13%	39%	39%	8%
Foshan Haitian-H	5/13/2026	85%	85%	4.2%	4.8%	4.1%	5.1%	21%	23%	55%	58%	13%

Price as of June 2.

Source: Company data, LSEG Data & Analytics, Goldman Sachs Global Investment Research



Valuation Comps

Exhibit 16: Coverage Valuation Comps with global peers

	Company	Rating	Mkt cap US\$ mn	Ccy	Price 6/2/2026	12-m TP	+/-	2026E	PE 2027E	2028E	TP Implied PE 2026E 2027E 2028E	26-28E Rev CAGR	26-28E NP CAGR	EV/EBITDA 2026E 2027E 2028E	ROE 2026E	Div yield 2026E	YTD perf %
Spirits																	
600519.SS	Kweichow Moutai	Buy	238,139	CNY	1307.22	1616.00	24%	19X	18X	17X	24X 22X 21X	6%	7%	12X 11X 11X	32%	4.0%	-5%
000858.SZ	Wuliangye Yibin	Sell	47,271	CNY	82.71	83.00	0%	18X	16X	14X	18X 16X 14X	12%	13%	10X 8X 7X	14%	6.3%	-22%
6979.HK	ZILD	Neutral	2,850	HKD	7.22	7.00	-3%	26X	19X	14X	25X 18X 14X	16%	33%	12X 9X 7X	6%	1.7%	-17%
600809.SS	Shanxi Xinghuacun Fen Wine	Neutral	22,283	CNY	125.70	161.00	28%	14X	13X	12X	18X 17X 15X	6%	8%	10X 9X 8X	26%	4.7%	-27%
000568.SZ	Luzhou Laojiao	Neutral	19,057	CNY	88.50	98.00	11%	14X	13X	12X	16X 15X 13X	7%	8%	8X 8X 7X	18%	5.4%	-24%
002304.SZ	Jiangsu Yanghe	Sell	9,810	CNY	44.69	38.00	-15%	17X	15X	n.a.	15X 13X n.a.	n.a.	n.a.	11X 10X n.a.	8%	9.9%	-26%
000596.SZ	Anhui Goujing Distillery Co.	Sell	7,074	CNY	93.05	129.00	39%	13X	11X	n.a.	17X 16X n.a.	n.a.	n.a.	7X 6X n.a.	14%	5.0%	-30%
000799.SZ	Jiugu Liquor	Sell	2,224	CNY	45.70	18.30	-60%	n.m.	44X	n.a.	n.m. 18X n.a.	n.a.	n.a.	n.m. 34X n.a.	5%	0.9%	-16%
600779.SS	Sichuan Sweetlun Co.	Sell	2,359	CNY	32.39	26.50	-18%	27X	21X	n.a.	22X 17X n.a.	n.a.	n.a.	15X 12X n.a.	10%	1.3%	-16%
603369.SS	Jiangsu King's Luck Brewery	Neutral	5,471	CNY	29.19	39.00	34%	12X	11X	n.a.	16X 15X n.a.	n.a.	n.a.	8X 7X n.a.	17%	3.5%	-16%
Avg.								18X	18X	14X	19X 17X 16X	9%	8%	10X 11X 8X	15%	4.3%	-20%
Beer																	
1876.HK	Budweiser APAC	Buy	11,936	HKD	7.11	8.80	24%	17X	16X	14X	22X 19X 17X	5%	13%	6X 5X 4X	7%	5.2%	-6%
0291.HK	China Resources Beer	Buy	9,960	HKD	24.14	34.73	44%	12X	11X	10X	17X 15X 14X	2%	7%	6X 5X 5X	17%	5.4%	-8%
0168.HK	Tsingtao Brewery (H)	Buy	8,481	HKD	50.25	62.00	23%	12X	11X	10X	15X 14X 13X	3%	8%	6X 6X 5X	15%	6.1%	3%
600600.SS	Tsingtao Brewery (A)	Neutral	11,951	CNY	61.01	67.60	11%	17X	16X	15X	19X 17X 16X	3%	8%	10X 9X 8X	15%	4.3%	0%
600132.SS	Chongqing Brewery	Neutral	3,715	CNY	52.90	50.00	-5%	20X	19X	17X	19X 18X 16X	3%	8%	7X 6X 6X	36%	5.0%	1%
002568.SZ	Shanghai Bairun	Neutral	2,990	CNY	19.88	20.00	1%	26X	21X	n.a.	26X 21X n.a.	n.a.	n.a.	16X 14X n.a.	15%	2.0%	-9%
Avg.								17X	15X	13X	19X 17X 15X	3%	8%	8X 8X 6X	17%	4.6%	-3%
Condiment																	
603288.SS	Foshan Haitian Flavouring & Food	Neutral	29,769	CNY	34.68	43.10	24%	26X	23X	21X	32X 28X 26X	8%	11%	18X 16X 15X	18%	3.3%	-6%
3288.HK	Foshan Haitian Flavouring & Food*	Buy	23,028	HKD	31.20	47.30	52%	21X	18X	16X	31X 27X 25X	8%	11%	14X 12X 11X	18%	4.2%	-4%
600872.SS	Jonjee Hi-Tech	Sell	2,179	CNY	18.97	16.00	-16%	21X	19X	17X	18X 16X 15X	9%	11%	15X 13X 12X	11%	3.0%	8%
1579.HK	Yihai International Holding	Buy	1,698	HKD	13.89	19.10	38%	12X	11X	10X	17X 15X 14X	5%	9%	6X 5X 5X	19%	7.6%	10%
603027.SS	Qianhe Condiment and Food	Sell	1,185	CNY	7.76	5.90	-24%	21X	19X	n.a.	16X 14X n.a.	n.a.	n.a.	10X 9X n.a.	13%	6.0%	-21%
603317.SS	Sichuan Teway Food Group	Sell	2,205	CNY	14.60	10.90	-25%	22X	19X	18X	16X 15X 13X	7%	10%	14X 13X 12X	15%	4.8%	17%
Avg.								20X	18X	17X	22X 19X 19X	7%	10%	13X 12X 11X	15.9%	5.3%	1%
Dairy																	
600887.SS	Yili Industrial	Buy	25,288	CNY	26.86	35.00	30%	14X	13X	12X	19X 17X 15X	3%	10%	11X 10X 9X	19%	5.1%	-6%
2319.HK	Mengniu Dairy	Buy	8,657	HKD	17.26	24.00	39%	12X	10X	9X	16X 14X 13X	6%	9%	7X 6X 5X	11%	4.3%	16%
6186.HK	China Felhe Ltd.	Neutral	3,742	HKD	3.28	3.43	5%	11X	10X	10X	11X 10X 10X	1%	3%	4X 4X 4X	9%	7.5%	-19%
Avg.								12X	11X	10X	15X 14X 13X	3%	8%	7X 7X 6X	13.2%	5.6%	-3%
F&B																	
9633.HK	Nongfu Spring	Buy	62,166	HKD	44.04	58.70	33%	24X	21X	18X	32X 28X 25X	12%	13%	15X 13X 12X	42%	3.0%	-6%
0322.HK	Tingyi	Neutral	9,214	HKD	12.63	12.60	0%	15X	14X	13X	15X 14X 13X	2%	8%	7X 7X 6X	22%	6.7%	7%
00220.HK	Uni-President China	Neutral	4,723	HKD	8.57	8.50	-1%	15X	14X	13X	15X 14X 13X	4%	6%	8X 8X 7X	16%	6.7%	5%
605496.SS	Eastro Beverage	Buy	15,630	CNY	149.60	184.60	23%	20X	18X	15X	25X 22X 19X	16%	16%	13X 12X 10X	33%	3.1%	-27%
2460.HK	China Resources Beverage	Neutral	2,491	HKD	8.18	8.20	0%	17X	15X	13X	17X 15X 13X	5%	13%	6X 5X 4X	9%	4.0%	-19%
Avg.								18X	17X	14X	21X 19X 16X	8%	11%	10X 9X 8X	24.5%	4.7%	-8%
Value retailer																	
300972.SZ	Fujian Wanchen Food	Buy	5,423	CNY	191.67	319.00	66%	14X	12X	11X	24X 20X 18X	11%	15%	6X 5X 4X	59%	1.0%	-5%
1768.HK	Busy Ming Group	Buy	9,734	HKD	361.40	550.00	52%	17X	13X	11X	26X 21X 17X	12%	22%	11X 8X 6X	34%	0.7%	53%
Avg.								16X	13X	11X	25X 20X 17X	11%	18%	9X 6X 5X	46.7%	0.8%	24%
Snacks																	
002557.SZ	Onacha Food Co.	Sell	1,622	CNY	22.50	20.90	-7%	15X	14X	13X	14X 13X 12X	4%	8%	9X 9X 8X	13%	3.9%	4%
002847.SZ	Yankershop Food	Buy	2,275	CNY	59.64	87.00	46%	18X	15X	13X	26X 22X 19X	14%	17%	13X 11X 9X	39%	3.0%	-13%
0151.HK	Want Want China	Sell	6,474	HKD	4.23	4.00	-5%	10X	10X	10X	9X 9X 9X	2%	0%	5X 5X 4X	20%	3.8%	-9%
9985.HK	Weilong Delicious Global Holdings	Buy	2,430	HKD	8.17	14.00	71%	11X	10X	9X	19X 16X 15X	9%	13%	4X 4X 3X	20%	5.6%	-27%
300783.SZ	Three Squirrels	Neutral	1,032	CNY	17.81	22.10	24%	18X	16X	15X	23X 20X 18X	7%	11%	12X 10X 8X	12%	1.7%	-23%
Avg.								15X	14X	13X	19X 17X 15X	7%	8%	9X 8X 7X	18.8%	2.0%	-12%
Frozen Food																	
603345.SS	Anjoy Foods Group	Neutral	4,425	CNY	93.97	106.00	13%	17X	15X	14X	19X 17X 15X	9%	14%	10X 9X 8X	11%	4.3%	19%
2648.HK	Anjoy Foods Group	Buy	2,722	HKD	75.80	98.00	29%	12X	10X	9X	15X 13X 12X	9%	13%	5X 4X 2X	11%	6.6%	15%
001215.SZ	Qianweiyangchu	Sell	572	CNY	39.15	24.30	-38%	40X	34X	31X	25X 21X 19X	6%	14%	15X 13X 12X	5%	0.0%	2%
300973.SZ	Ligao Foods	Buy	676	CNY	27.59	44.00	59%	14X	12X	10X	23X 19X 17X	9%	17%	7X 7X 6X	12%	1.9%	-36%
002216.SZ	Sanquan Foods	Neutral	1,664	CNY	13.08	11.00	-16%	18X	18X	18X	15X 15X 15X	2%	2%	16X 16X 15X	13%	5.1%	16%
600298.SS	Angel Yeast	Buy	4,547	CNY	36.86	45.10	22%	16X	16X	16X	20X 19X 19X	9%	2%	10X 10X 9X	14%	1.6%	-16%
Avg.								22X	20X	19X	21X 19X 17X	7%	9%	12X 11X 11X	11.2%	2.1%	-9%
Pet Care																	
002891.SZ	China Pet Foods	Neutral	1,368	CNY	30.10	36.00	20%	24X	15X	11X	28X 18X 13X	19%	46%	15X 10X 7X	12%	1.3%	-42%
300673.SZ	Petpal Pet Nutrition Technology	Sell	578	CNY	15.36	12.70	-17%	23X	19X	15X	19X 16X 13X	14%	24%	12X 10X 8X	8%	0.8%	-14%
301498.SZ	Gambol Pet Group Co.	Neutral	2,532	CNY	43.73	66.00	51%	25X	18X	14X	38X 27X 21X	17%	33%	16X 11X 9X	14%	1.2%	-33%
Avg.								24X	17X	13X	28X 20X 16X	17%	35%	14X 11X 8X	11.4%	1.1%	-30%
Pork																	
0288.HK	WH Group	Buy	14,734	HKD	9.10	11.80	30%	9X	9X	9X	12X 12X 12X	3%	1%	4X 4X 4X	12%	6.9%	5%
000895.SZ	Henan Shuanghui Ltd.	Neutral	12,619	CNY	24.93	27.00	8%	16X	17X	17X	17X 18X 18X	2%	-4%	10X 10X 10X	25%	6.2%	-6%
Avg.								13X	13X	13X	15X 15X 15X	2%	-1%	7X 7X 7X	18.5%	6.6%	0%

Disclosure Appendix

Reg AC

We, Leaf Liu, Valerie Zhou and Christina Liu, hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Goldman Sachs' Global Investment Research division.

Contributing Authors: Leaf Liu Goldman Sachs (Asia) L.L.C., Valerie Zhou Goldman Sachs (Asia) L.L.C., Christina Liu Goldman Sachs (Asia) L.L.C..

Unless otherwise stated, the individuals listed in the Contributing Authors disclosure of this report are analysts in Goldman Sachs' Global Investment Research division.

GS Factor Profile

The Goldman Sachs Factor Profile provides investment context for a stock by comparing key attributes to the market (i.e. our universe of rated stocks) and its sector peers. The four key attributes depicted are: Growth, Financial Returns, Multiple (e.g. valuation) and Integrated (a composite of Growth, Financial Returns and Multiple). Growth, Financial Returns and Multiple are calculated by using normalized ranks for specific metrics for each stock. The normalized ranks for the metrics are then averaged and converted into percentiles for the relevant attribute. The precise calculation of each metric may vary depending on the fiscal year, industry and region, but the standard approach is as follows:

Growth is based on a stock's forward-looking sales growth, EBITDA growth and EPS growth (for financial stocks, only EPS and sales growth), with a higher percentile indicating a higher growth company. **Financial Returns** is based on a stock's forward-looking ROE, ROCE and CROCI (for financial stocks, only ROE), with a higher percentile indicating a company with higher financial returns. **Multiple** is based on a stock's forward-looking P/E, P/B, price/dividend (P/D), EV/EBITDA, EV/FCF and EV/Debt Adjusted Cash Flow (DACF) (for financial stocks, only P/E, P/B and P/D), with a higher percentile indicating a stock trading at a higher multiple. The **Integrated** percentile is calculated as the average of the Growth percentile, Financial Returns percentile and (100% - Multiple percentile).

Financial Returns and Multiple use the Goldman Sachs analyst forecasts at the fiscal year-end at least three quarters in the future. Growth uses inputs for the fiscal year at least seven quarters in the future compared with the year at least three quarters in the future (on a per-share basis for all metrics).

For a more detailed description of how we calculate the GS Factor Profile, please contact your GS representative.

M&A Rank

Across our global coverage, we examine stocks using an M&A framework, considering both qualitative factors and quantitative factors (which may vary across sectors and regions) to incorporate the potential that certain companies could be acquired. We then assign a M&A rank as a means of scoring companies under our rated coverage from 1 to 3, with 1 representing high (30%-50%) probability of the company becoming an acquisition target, 2 representing medium (15%-30%) probability and 3 representing low (0%-15%) probability. For companies ranked 1 or 2, in line with our standard departmental guidelines we incorporate an M&A component into our target price. M&A rank of 3 is considered immaterial and therefore does not factor into our price target, and may or may not be discussed in research.

Quantum

Quantum is Goldman Sachs' proprietary database providing access to detailed financial statement histories, forecasts and ratios. It can be used for in-depth analysis of a single company, or to make comparisons between companies in different sectors and markets.

Disclosures

Distribution of ratings/investment banking relationships

Goldman Sachs Investment Research global Equity coverage universe

	Rating Distribution				Investment Banking Relationships		
	Buy	Hold	Sell		Buy	Hold	Sell
Global	50%	34%	16%		65%	60%	45%

As of April 1, 2026, Goldman Sachs Global Investment Research had investment ratings on 3,074 equity securities. Goldman Sachs assigns stocks as Buys and Sells on various regional Investment Lists; stocks not so assigned are deemed Neutral. Such assignments equate to Buy, Hold and Sell for the purposes of the above disclosure required by the FINRA Rules. See 'Ratings, Coverage universe and related definitions' below. The Investment Banking Relationships chart reflects the percentage of subject companies within each rating category for whom Goldman Sachs has provided investment banking services within the previous twelve months.

Regulatory disclosures

Disclosures required by United States laws and regulations

See company-specific regulatory disclosures above for any of the following disclosures required as to companies referred to in this report: manager or co-manager in a pending transaction; 1% or other ownership; compensation for certain services; types of client relationships; managed/co-managed public offerings in prior periods; directorships; for equity securities, market making and/or specialist role. Goldman Sachs trades or may trade as a principal in debt securities (or in related derivatives) of issuers discussed in this report.

The following are additional required disclosures: **Ownership and material conflicts of interest:** Goldman Sachs policy prohibits its analysts, professionals reporting to analysts and members of their households from owning securities of any company in the analyst's area of coverage. **Analyst compensation:** Analysts are paid in part based on the profitability of Goldman Sachs, which includes investment banking revenues. **Analyst as officer or director:** Goldman Sachs policy generally prohibits its analysts, persons reporting to analysts or members of their households from serving as an officer, director or advisor of any company in the analyst's area of coverage. **Non-U.S. Analysts:** Non-U.S. analysts may not be associated persons of Goldman Sachs & Co. LLC and therefore may not be subject to FINRA Rule 2241 or FINRA Rule 2242 restrictions on communications with a subject company, public appearances and trading in securities covered by the analysts.

Distribution of ratings: See the distribution of ratings disclosure above. **Price chart:** See the price chart, with changes of ratings and price targets in

prior periods, above, or, if electronic format or if with respect to multiple companies which are the subject of this report, on the Goldman Sachs website at <https://www.gs.com/research/hedge.html>.

Additional disclosures required under the laws and regulations of jurisdictions other than the United States

The following disclosures are those required by the jurisdiction indicated, except to the extent already made above pursuant to United States laws and regulations. **Australia:** Goldman Sachs Australia Pty Ltd and its affiliates are not authorised deposit-taking institutions (as that term is defined in the Banking Act 1959 (Cth)) in Australia and do not provide banking services, nor carry on a banking business, in Australia. This research, and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act, unless otherwise agreed by Goldman Sachs. In producing research reports, members of Global Investment Research of Goldman Sachs Australia may attend site visits and other meetings hosted by the companies and other entities which are the subject of its research reports. In some instances the costs of such site visits or meetings may be met in part or in whole by the issuers concerned if Goldman Sachs Australia considers it is appropriate and reasonable in the specific circumstances relating to the site visit or meeting. To the extent that the contents of this document contains any financial product advice, it is general advice only and has been prepared by Goldman Sachs without taking into account a client's objectives, financial situation or needs. A client should, before acting on any such advice, consider the appropriateness of the advice having regard to the client's own objectives, financial situation and needs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests and a copy of Goldman Sachs' Australian Sell-Side Research Independence Policy Statement are available at: <https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html>. **Brazil:** Disclosure information in relation to CVM Resolution n. 20 is available at <https://www.gs.com/worldwide/brazil/area/gir/index.html>. Where applicable, the Brazil-registered analyst primarily responsible for the content of this research report, as defined in Article 20 of CVM Resolution n. 20, is the first author named at the beginning of this report, unless indicated otherwise at the end of the text. **Canada:** This information is being provided to you for information purposes only and is not, and under no circumstances should be construed as, an advertisement, offering or solicitation by Goldman Sachs & Co. LLC for purchasers of securities in Canada to trade in any Canadian security. Goldman Sachs & Co. LLC is not registered as a dealer in any jurisdiction in Canada under applicable Canadian securities laws and generally is not permitted to trade in Canadian securities and may be prohibited from selling certain securities and products in certain jurisdictions in Canada. If you wish to trade in any Canadian securities or other products in Canada please contact Goldman Sachs Canada Inc., an affiliate of The Goldman Sachs Group Inc., or another registered Canadian dealer. **Hong Kong:** Further information on the securities of covered companies referred to in this research may be obtained on request from Goldman Sachs (Asia) L.L.C. **India:** Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (India) Securities Private Limited, Research Analyst - SEBI Registration Number INH000001493, 10th Floor, Ascent-Worli, Sudam Kalu Ahire Marg, Worli, Mumbai-400 025, India, Corporate Identity Number U74140MH2006FTC160634, Phone +91 22 6616 9000, Fax +91 22 6616 9001. Goldman Sachs may beneficially own 1% or more of the securities (as such term is defined in clause 2 (h) the Indian Securities Contracts (Regulation) Act, 1956) of the subject company or companies referred to in this research report. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Goldman Sachs (India) Securities Private Limited compliance officer and investor grievance contact details can be found at: <https://www.goldmansachs.com/worldwide/india/documents/Grievance-Redressal-and-Escalation-Matrix.pdf>, and a copy of the annual audit compliance report can be found at this link: <https://publishing.gs.com/content/site/india-annual-compliance-report.html>. **Japan:** See below. **Korea:** This research, and any access to it, is intended only for "professional investors" within the meaning of the Financial Services and Capital Markets Act, unless otherwise agreed by Goldman Sachs. Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (Asia) L.L.C., Seoul Branch. **New Zealand:** Goldman Sachs New Zealand Limited and its affiliates are neither "registered banks" nor "deposit takers" (as defined in the Reserve Bank of New Zealand Act 1989) in New Zealand. This research, and any access to it, is intended for "wholesale clients" (as defined in the Financial Advisers Act 2008) unless otherwise agreed by Goldman Sachs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests is available at: <https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html>. **Russia:** Research reports distributed in the Russian Federation are not advertising as defined in the Russian legislation, but are information and analysis not having product promotion as their main purpose and do not provide appraisal within the meaning of the Russian legislation on appraisal activity. Research reports do not constitute a personalized investment recommendation as defined in Russian laws and regulations, are not addressed to a specific client, and are prepared without analyzing the financial circumstances, investment profiles or risk profiles of clients. Goldman Sachs assumes no responsibility for any investment decisions that may be taken by a client or any other person based on this research report. **Singapore:** Goldman Sachs (Singapore) Pte. (Company Number: 198602165W), which is regulated by the Monetary Authority of Singapore, accepts legal responsibility for this research, and should be contacted with respect to any matters arising from, or in connection with, this research. **Taiwan:** This material is for reference only and must not be reprinted without permission. Investors should carefully consider their own investment risk. Investment results are the responsibility of the individual investor. **United Kingdom:** Persons who would be categorized as retail clients in the United Kingdom, as such term is defined in the rules of the Financial Conduct Authority, should read this research in conjunction with prior Goldman Sachs research on the covered companies referred to herein and should refer to the risk warnings that have been sent to them by Goldman Sachs International. A copy of these risks warnings, and a glossary of certain financial terms used in this report, are available from Goldman Sachs International on request.

European Union and United Kingdom: Disclosure information in relation to Article 6 (2) of the European Commission Delegated Regulation (EU) (2016/958) supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council (including as that Delegated Regulation is implemented into United Kingdom domestic law and regulation following the United Kingdom's departure from the European Union and the European Economic Area) with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest is available at <https://www.gs.com/disclosures/europeanpolicy.html> which states the European Policy for Managing Conflicts of Interest in Connection with Investment Research.

Japan: Goldman Sachs Japan Co., Ltd. is a Financial Instrument Dealer registered with the Kanto Financial Bureau under registration number Kinsho 69, and a member of Japan Securities Dealers Association, Financial Futures Association of Japan Type II Financial Instruments Firms Association, and Investment Management Association of Japan. Sales and purchase of equities are subject to commission pre-determined with clients plus consumption tax. See company-specific disclosures as to any applicable disclosures required by Japanese stock exchanges, the Japanese Securities Dealers Association or the Japanese Securities Finance Company.

Ratings, coverage universe and related definitions

Buy (B), Neutral (N), Sell (S) Analysts recommend stocks as Buys or Sells for inclusion on various regional Investment Lists. Being assigned a Buy or Sell on an Investment List is determined by a stock's total return potential relative to its coverage universe. Any stock not assigned as a Buy or a Sell on an Investment List with an active rating (i.e., a stock that is not Rating Suspended, Not Rated, Early-Stage Biotech, Coverage Suspended or Not Covered), is deemed Neutral. Each region manages Regional Conviction Lists, which are selected from Buy rated stocks on the respective region's Investment Lists and represent investment recommendations focused on the size of the total return potential and/or the likelihood of the realization of the return across their respective areas of coverage. The addition or removal of stocks from such Conviction Lists are managed by the Investment Review Committee or other designated committee in each respective region and do not represent a change in the analysts' investment rating for such stocks.

Total return potential represents the upside or downside differential between the current share price and the price target, including all paid or anticipated dividends, expected during the time horizon associated with the price target. Price targets are required for all covered stocks. The total return potential, price target and associated time horizon are stated in each report adding or reiterating an Investment List membership.

Coverage Universe: A list of all stocks in each coverage universe is available by primary analyst, stock and coverage universe at <https://www.gs.com/research/hedge.html>.

Not Rated (NR). The investment rating, target price and earnings estimates (where relevant) are removed pursuant to Goldman Sachs policy when Goldman Sachs is acting in an advisory capacity in a merger or in a strategic transaction involving this company, when there are legal, regulatory or policy constraints due to Goldman Sachs' involvement in a transaction, and in certain other circumstances. **Early-Stage Biotech (ES).** An investment rating and a target price are not assigned pursuant to Goldman Sachs policy when this company has neither a drug, treatment or medical device that has passed a Phase II clinical trial nor a license to distribute a post-Phase II drug, treatment or medical device. **Rating Suspended (RS).** Goldman Sachs Research has suspended the investment rating and price target for this stock, because there is not a sufficient fundamental basis for determining an investment rating or target price. The previous investment rating and target price, if any, are no longer in effect for this stock and should not be relied upon. **Coverage Suspended (CS).** Goldman Sachs has suspended coverage of this company. **Not Covered (NC).** Goldman Sachs does not cover this company.

Global product; distributing entities

Goldman Sachs Global Investment Research produces and distributes research products for clients of Goldman Sachs on a global basis. Analysts based in Goldman Sachs offices around the world produce research on industries and companies, and research on macroeconomics, currencies, commodities and portfolio strategy. This research is disseminated in Australia by Goldman Sachs Australia Pty Ltd (ABN 21 006 797 897); in Brazil by Goldman Sachs do Brasil Corretora de Títulos e Valores Mobiliários S.A.; Public Communication Channel Goldman Sachs Brazil: 0800 727 5764 and / or contatogoldmanbrasil@gs.com. Available Weekdays (except holidays), from 9am to 6pm. Canal de Comunicação com o Público Goldman Sachs Brasil: 0800 727 5764 e/ou contatogoldmanbrasil@gs.com. Horário de funcionamento: segunda-feira à sexta-feira (exceto feriados), das 9h às 18h; in Canada by Goldman Sachs & Co. LLC; in Hong Kong by Goldman Sachs (Asia) L.L.C.; in India by Goldman Sachs (India) Securities Private Ltd.; in Japan by Goldman Sachs Japan Co., Ltd.; in the Republic of Korea by Goldman Sachs (Asia) L.L.C., Seoul Branch; in New Zealand by Goldman Sachs New Zealand Limited; in Russia by OOO Goldman Sachs; in Singapore by Goldman Sachs (Singapore) Pte. (Company Number: 198602165W); and in the United States of America by Goldman Sachs & Co. LLC. Goldman Sachs International has approved this research in connection with its distribution in the United Kingdom.

Goldman Sachs International ("GSI"), authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority ("FCA") and the PRA, has approved this research in connection with its distribution in the United Kingdom.

European Economic Area: Goldman Sachs Bank Europe SE ("GSBE") is a credit institution incorporated in Germany and, within the Single Supervisory Mechanism, subject to direct prudential supervision by the European Central Bank and in other respects supervised by German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) and Deutsche Bundesbank and disseminates research within the European Economic Area.

General disclosures

This research is for our clients only. Other than disclosures relating to Goldman Sachs, this research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. The information, opinions, estimates and forecasts contained herein are as of the date hereof and are subject to change without prior notification. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the analyst's judgment.

Goldman Sachs conducts a global full-service, integrated investment banking, investment management, and brokerage business. We have investment banking and other business relationships with a substantial percentage of the companies covered by Global Investment Research. Goldman Sachs & Co. LLC, the United States broker dealer, is a member of SIPC (<https://www.sipc.org>).

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and principal trading desks that reflect opinions that are contrary to the opinions expressed in this research. Our asset management area, principal trading desks and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

The analysts named in this report may have from time to time discussed with our clients, including Goldman Sachs salespersons and traders, or may discuss in this report, trading strategies that reference catalysts or events that may have a near-term impact on the market price of the equity securities discussed in this report, which impact may be directionally counter to the analyst's published price target expectations for such stocks. Any such trading strategies are distinct from and do not affect the analyst's fundamental equity rating for such stocks, which rating reflects a stock's return potential relative to its coverage universe as described herein.

We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this research, unless otherwise prohibited by regulation or Goldman Sachs policy.

The views attributed to third party presenters at Goldman Sachs arranged conferences, including individuals from other parts of Goldman Sachs, do not necessarily reflect those of Global Investment Research and are not an official view of Goldman Sachs.

Any third party referenced herein, including any salespeople, traders and other professionals or members of their household, may have positions in the products mentioned that are inconsistent with the views expressed by analysts named in this report.

This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Investors should review current options and futures disclosure documents which are available from Goldman Sachs sales representatives or at <https://www.theocc.com/about/publications/character-risks.jsp> and https://www.goldmansachs.com/disclosures/cftc_fcm_disclosures. Transaction costs may be significant in option strategies calling for multiple purchase and sales of options such as spreads. Supporting documentation will be supplied upon request.

Differing Levels of Service provided by Global Investment Research: The level and types of services provided to you by Goldman Sachs Global Investment Research may vary as compared to that provided to internal and other external clients of GS, depending on various factors including your individual preferences as to the frequency and manner of receiving communication, your risk profile and investment focus and perspective (e.g., marketwide, sector specific, long term, short term), the size and scope of your overall client relationship with GS, and legal and regulatory constraints. As an example, certain clients may request to receive notifications when research on specific securities is published, and certain clients may request that specific data underlying analysts' fundamental analysis available on our internal client websites be delivered to them electronically through data

feeds or otherwise. No change to an analyst's fundamental research views (e.g., ratings, price targets, or material changes to earnings estimates for equity securities), will be communicated to any client prior to inclusion of such information in a research report broadly disseminated through electronic publication to our internal client websites or through other means, as necessary, to all clients who are entitled to receive such reports.

All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client websites. Not all research content is redistributed to our clients or available to third-party aggregators, nor is Goldman Sachs responsible for the redistribution of our research by third party aggregators. For research, models or other data related to one or more securities, markets or asset classes (including related services) that may be available to you, please contact your GS representative or go to <https://research.gs.com>.

Disclosure information is also available at <https://www.gs.com/research/hedge.html> or from Research Compliance, 200 West Street, New York, NY 10282.

© 2026 Goldman Sachs.

You are permitted to store, display, analyze, modify, reformat, and print the information made available to you via this service only for your own use. You may not resell or reverse engineer this information to calculate or develop any index for disclosure and/or marketing or create any other derivative works or commercial product(s), data or offering(s) without the express written consent of Goldman Sachs. You are not permitted to publish, transmit, or otherwise reproduce this information, in whole or in part, in any format to any third party without the express written consent of Goldman Sachs. This foregoing restriction includes, without limitation, using, extracting, downloading or retrieving this information, in whole or in part, to train or finetune a machine learning or artificial intelligence system, or to provide or reproduce this information, in whole or in part, as a prompt or input to any such system.